# Krystal Biotech (KRYS) — News

KRYS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/krys/news

## Recent headlines

- [Krystal Biotech - KB113 injections well tolerated with only mild to moderate transient adverse events](https://www.ainvest.com/news/krystal-biotech-kb113-injections-tolerated-mild-moderate-transient-adverse-events-2610) — AInvest Wire, Oct 15, 2026
  Krystal Biotech Inc. (NASDAQ: KRYS) has reported that its KB113 injections were well tolerated in clinical trials, with adverse events primarily classified as mild to moderate and transient in nature. These findings are consistent with the company’s ongoing efforts to develop a safe and effective…
- [Krystal Biotech - Substantial regression observed in non-injected lesions with KB113](https://www.ainvest.com/news/krystal-biotech-substantial-regression-observed-injected-lesions-kb113-2610) — AInvest Wire, Oct 15, 2026
- [Krispy Kreme announces development deal to expand across the New York metro area](https://www.ainvest.com/news/krispy-kreme-announces-development-deal-expand-york-metro-area-2610) — AInvest Wire, Oct 13, 2026
- [Krystal Biotech, Inc.: RBC initiates coverage with outperform rating; target price $400](https://www.ainvest.com/news/krystal-biotech-rbc-initiates-coverage-outperform-rating-target-price-400-2608) — AInvest Wire, Aug 14, 2026
  RBC Capital Markets has initiated coverage of Krystal Biotech, Inc. (NASDAQ: KRBK) with an "outperform" rating and a target price of $400 per share. The firm cited the company’s progress in advancing its lead gene therapy candidate, KB105, for the treatment of recessive dystrophic epidermolysis…
- [Krystal Biotech shares down 7.2% after Q2 results](https://www.ainvest.com/news/krystal-biotech-shares-7-2-q2-results-2608) — AInvest Wire, Aug 3, 2026
  Krystal Biotech (NASDAQ: KRYS) shares fell 7.2% following the release of its second-quarter 2026 financial results, despite strong revenue growth and continued expansion of its flagship product, VYJUVEK. The company reported $119.2 million in product revenue for the quarter, up from $96.0 million…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).